Ozanimod for treating relapsing–remitting multiple sclerosis

2.1 Ozanimod (Zeposia, Celgene) is indicated for 'the treatment of adult patients with relapsing remitting multiple sclerosis with active disease as defined by clinical or imaging features'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price for ozanimod is £1,373 per maintenance pack of 28 capsules, each containing 1 mg ozanimod hydrochloride (equivalent to 0.92 mg of ozanimod; excluding VAT; BNF online, accessed April 2021). The company has a commercial arrangement, which would have applied if the technology had been recommended.